Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 24.94 USD -3.59% Market Closed
Market Cap: 1.9B USD

During the last 3 months Zymeworks Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 58% over this period (open performance analysis).

The last transaction was made on May 19, 2025 by Nodelman Oleg , who bought 69.7k USD worth of ZYME shares.

Last Transactions:
Nodelman Oleg
$+69.7k
Nodelman Oleg
$+565.8k
Nodelman Oleg
$+630.8k
Nodelman Oleg
$+825.6k
Nodelman Oleg
$+2.2m
Nodelman Oleg
$+1.4m
Nodelman Oleg
$+881k
Nodelman Oleg
$+564.6k
Nodelman Oleg
$+51.7k
Nodelman Oleg
$+536.9k
Nodelman Oleg
$+690.5k
Nodelman Oleg
$+296.8k
Nodelman Oleg
$+396.5k
Nodelman Oleg
$+949.9k
Nodelman Oleg
$+737.2k
Nodelman Oleg
$+1.4m
Nodelman Oleg
$+688.5k
Nodelman Oleg
$+5.8m
Nodelman Oleg
$+3.6m
Nodelman Oleg
$+3.7m
Ecor1 Capital, Llc
$+274k
Ecor1 Capital, Llc
$+1.7m
Ecor1 Capital, Llc
$+546.7k
Ecor1 Capital, Llc
$+739.3k
Ecor1 Capital, Llc
$+992.9k
Ecor1 Capital, Llc
$+2.7m
Ecor1 Capital, Llc
$+295.8k
Smith Jeffrey T L
$-165.8k
Galbraith Kenneth
$-356.5k
Moore Paul Andrew
$-146.1k
Ecor1 Capital, Llc
$+2.3m
Ecor1 Capital, Llc
$+2.1m
View All Transactions

During the last 3 months Zymeworks Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 58% over this period (open performance analysis).

The last transaction was made on May 19, 2025 by Nodelman Oleg , who bought 69.7k USD worth of ZYME shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
668.4k USD
3
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
1
18.8m USD
9-12
months
2
39.2m USD

Zymeworks Inc
Insider Trading Chart

Zymeworks Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Zymeworks Inc
Last Insider Transactions

Global
Insiders Monitor

Zymeworks Inc
Glance View

Market Cap
1.9B USD
Industry
Biotechnology

Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

ZYME Intrinsic Value
HIDDEN
Show

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top